Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ColonCan

Financiado

Cerrado

Targeting downstream effectors of Wnt signaling in colorectal cancer

Colorectal cancer (CRC) is one of the most common cancers of the western world. The underlying initiating mutation for the majority of CRC is within the Adenomatous Polyposis Coli (Apc) gene. The APC protein performs an important... ver más

31/10/2017

BEATSON INSTITUTE...

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

BEATSON INSTITUTE FOR CANCER RESEARCH LBG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-10-31 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

BEATSON INSTITUTE FOR CANCER...

0.00€ | Lider

Proyectos interesantes

SAF2008-01512

Medical Technol...

Data Science

351K€ Cerrado

SAF2009-07319

Medical Technol...

Genetics

334K€ Cerrado

Wnt and CRC

Medical Technol...

Applied Physics

170K€ Cerrado

CRC PROGRAMME

Medical Technol...

Data Science

2M€ Cerrado

WNT IN THE INTESTINE

Medical Technol...

Data Science

184K€ Cerrado

proCOLON

Medical Technol...

Pharmaceuticals

150K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

BEATSON INSTITUTE FOR CANCER RESEARCH LBG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Colorectal cancer (CRC) is one of the most common cancers of the western world. The underlying initiating mutation for the majority of CRC is within the Adenomatous Polyposis Coli (Apc) gene. The APC protein performs an important role in controlling the levels of Wnt signalling by targeting beta-catenin for degradation. Loss of the APC protein leads to the activation of Wnt signaling target genes such as c-Myc which is required for phenotypes causes by Apc loss. However, despite the clear importance of APC loss and deregulated Wnt signalling, additional events are required for the development of CRC such as KRAS and P53 mutations.The impact of these changes on the development of CRC and response to therapy is not well understood. Furthermore, identification and testing of potential novel targets and therapies is hampered by lack of a preclinical model that faithfully recapitulates the course of the human disease. This proposal has two aims: 1. Assess the impact of cooperating mutations with Apc and assess how they alter sensitivities of Apc deficient cells. 2. Develop mouse models of invasive and metastatic colorectal cancer that recapitulate the human disease. We will use ‘state of the art’ methodologies to identify the changes in signaling output conferred by these cooperating mutations. Genetic mouse models of invasive and metastatic colorectal cancers will be generated through the acquisition of additional mutations and genomic instability. These studies will produce predictions on therapeutic combinations that will be tested in mouse models in vitro and in vivo that may identify new treatment regimens for patients with late stage CRC.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores